In this study, we evaluated the combination of primary and expanded human γδ T cells with CD19 antibodies for immunotherapy of pediatric B-lineage ALL and established an label-free method, facilitating the long-term and real-time monitoring of γδ T cell-mediated antibody-independent (AIC) and ADCC. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.